MA60250B1 - 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile - Google Patents
1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrileInfo
- Publication number
- MA60250B1 MA60250B1 MA60250A MA60250A MA60250B1 MA 60250 B1 MA60250 B1 MA 60250B1 MA 60250 A MA60250 A MA 60250A MA 60250 A MA60250 A MA 60250A MA 60250 B1 MA60250 B1 MA 60250B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrrolidine
- benzyloxy
- difluoro
- benzoyl
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382606 | 2020-07-07 | ||
| EP21739678.7A EP4178945B1 (en) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
| PCT/EP2021/068577 WO2022008477A1 (en) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA60250B1 true MA60250B1 (fr) | 2024-11-29 |
Family
ID=71607883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA60250A MA60250B1 (fr) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12459891B2 (enExample) |
| EP (1) | EP4178945B1 (enExample) |
| JP (1) | JP7628716B2 (enExample) |
| KR (1) | KR20230035604A (enExample) |
| CN (1) | CN117545738A (enExample) |
| AU (1) | AU2021303440A1 (enExample) |
| BR (1) | BR112023000335A2 (enExample) |
| CA (1) | CA3185064A1 (enExample) |
| ES (1) | ES2997164T3 (enExample) |
| HR (1) | HRP20241527T1 (enExample) |
| HU (1) | HUE068953T2 (enExample) |
| IL (1) | IL299035B1 (enExample) |
| MA (1) | MA60250B1 (enExample) |
| MX (1) | MX2023000261A (enExample) |
| RS (1) | RS66215B1 (enExample) |
| SM (1) | SMT202400460T1 (enExample) |
| TW (1) | TWI893162B (enExample) |
| WO (1) | WO2022008477A1 (enExample) |
| ZA (1) | ZA202213708B (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159938A (en) | 1994-11-21 | 2000-12-12 | Cortech, Inc. | Serine protease inhibitors comprising α-keto heterocycles |
| DE19603510A1 (de) | 1996-02-01 | 1997-08-07 | Knoell Hans Forschung Ev | Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase |
| FI20011466A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö |
| FI20030014A0 (fi) | 2003-01-03 | 2003-01-03 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä |
| FI20031018A0 (fi) | 2003-07-04 | 2003-07-04 | Orion Corp | Parannus aivovammasta toipumiseen |
| WO2005027934A1 (ja) | 2003-09-24 | 2005-03-31 | Nippon Kayaku Kabushiki Kaisha | プロリルオリゴペプチダーゼ阻害剤 |
| US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| ES2302473B1 (es) | 2006-12-22 | 2009-06-12 | Universidad De Barcelona | Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos. |
| EP2730571A1 (en) * | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
-
2021
- 2021-07-06 AU AU2021303440A patent/AU2021303440A1/en active Pending
- 2021-07-06 RS RS20241253A patent/RS66215B1/sr unknown
- 2021-07-06 WO PCT/EP2021/068577 patent/WO2022008477A1/en not_active Ceased
- 2021-07-06 HR HRP20241527TT patent/HRP20241527T1/hr unknown
- 2021-07-06 MX MX2023000261A patent/MX2023000261A/es unknown
- 2021-07-06 TW TW110124773A patent/TWI893162B/zh active
- 2021-07-06 EP EP21739678.7A patent/EP4178945B1/en active Active
- 2021-07-06 HU HUE21739678A patent/HUE068953T2/hu unknown
- 2021-07-06 JP JP2022581707A patent/JP7628716B2/ja active Active
- 2021-07-06 CA CA3185064A patent/CA3185064A1/en active Pending
- 2021-07-06 SM SM20240460T patent/SMT202400460T1/it unknown
- 2021-07-06 CN CN202180047448.7A patent/CN117545738A/zh active Pending
- 2021-07-06 US US18/004,658 patent/US12459891B2/en active Active
- 2021-07-06 MA MA60250A patent/MA60250B1/fr unknown
- 2021-07-06 ES ES21739678T patent/ES2997164T3/es active Active
- 2021-07-06 BR BR112023000335A patent/BR112023000335A2/pt unknown
- 2021-07-06 KR KR1020237003988A patent/KR20230035604A/ko active Pending
-
2022
- 2022-12-12 IL IL299035A patent/IL299035B1/en unknown
- 2022-12-19 ZA ZA2022/13708A patent/ZA202213708B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202213708B (en) | 2024-04-24 |
| IL299035A (en) | 2023-02-01 |
| TWI893162B (zh) | 2025-08-11 |
| JP7628716B2 (ja) | 2025-02-12 |
| SMT202400460T1 (it) | 2025-01-14 |
| EP4178945B1 (en) | 2024-08-28 |
| BR112023000335A2 (pt) | 2023-01-31 |
| US12459891B2 (en) | 2025-11-04 |
| AU2021303440A1 (en) | 2023-02-02 |
| CN117545738A (zh) | 2024-02-09 |
| EP4178945C0 (en) | 2024-08-28 |
| US20230250058A1 (en) | 2023-08-10 |
| WO2022008477A1 (en) | 2022-01-13 |
| ES2997164T3 (en) | 2025-02-14 |
| EP4178945A1 (en) | 2023-05-17 |
| CA3185064A1 (en) | 2022-01-13 |
| HUE068953T2 (hu) | 2025-02-28 |
| MX2023000261A (es) | 2023-04-13 |
| JP2023533932A (ja) | 2023-08-07 |
| TW202216689A (zh) | 2022-05-01 |
| KR20230035604A (ko) | 2023-03-14 |
| HRP20241527T1 (hr) | 2025-01-03 |
| IL299035B1 (en) | 2026-03-01 |
| RS66215B1 (sr) | 2024-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA59968B1 (fr) | Composés de cyclobutyle dihydroquinoléine sulfonamide | |
| MA63501B1 (fr) | Dérivés d'urée pouvant être utilisés pour traiter le cancer | |
| MA30073B1 (fr) | Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine | |
| MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| MA29379B1 (fr) | Derives de pyrrolidine 3,4-substitues pour le traitement de l'hypertension | |
| MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
| MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA27142A1 (fr) | Derives de piperazine a activite antagoniste des recepteurs ccr1 | |
| MA31800B1 (fr) | Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| MA30778B1 (fr) | Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques | |
| MA29213B1 (fr) | Quinolones a substitution macrolones - amino | |
| MA59447B1 (fr) | Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6 pour le traitement du cancer | |
| MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
| TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| MA29810B1 (fr) | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques | |
| MA29839B1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA28667B1 (fr) | Derives d'acide benzimidazolonecarboxylique | |
| MA31863B1 (fr) | Dérivés de pyrazole comme inhibiteurs de 5-lo | |
| HRP20010484A2 (en) | Substituted benzimidazoles and their preparation and use |